Table 3
Summary of drug related* treatment emergent adverse events
| Percentage of patients (%) | |||
|---|---|---|---|
| Category | Timolol + unoprostone (n=50) | Timolol + brimonidine (n=48) | Timolol + dorzolamide (n=48) |
| *Considered by the investigator to be related or possibly related to study medication. | |||
| †Events that occurred in >4% of the patients in any treatment group during adjunctive therapy. | |||
| Overall summary: | |||
| One or more drug related adverse events | 22.0 | 22.9 | 29.2 |
| Ocular event | 18.0 | 10.4 | 22.9 |
| Non-ocular event | 4.0 | 14.6 | 16.7 |
| Most common† drug related events: | |||
| Abnormal vision | 0.0 | 4.2 | 0.0 |
| Burning/stinging | 4.0 | 4.2 | 14.6 |
| Burning/stinging upon drug instillation | 8.0 | 0.0 | 2.1 |
| Dry mouth | 0.0 | 2.1 | 4.2 |
| Foreign body sensation | 4.0 | 4.2 | 0.0 |
| Headache | 0.0 | 4.2 | 2.1 |
| Hypertension | 0.0 | 4.2 | 0.0 |
| Itching | 0.0 | 8.3 | 0.0 |
| Lacrimation disorder | 2.0 | 2.1 | 4.2 |
| Nausea | 0.0 | 0.0 | 4.2 |
| Tachycardia | 0.0 | 2.1 | 4.2 |
| Taste perversion | 0.0 | 0.0 | 4.2 |
| Vertigo | 0.0 | 2.1 | 6.3 |
